Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SLEEP THERAPY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 793 records · Page 44Linked to original sources
PubMed1995

[Nicotine as therapy of obstructive sleep apnea?].

In 8 smokers (age 57 +/- 6 years, BMI 26.4 +/- 3.8 kg/m2) with an apnea-hypopnea index of 22.2 +/- 19.5 and who wanted to give up smoking with the help of nicotine plaster, various characteristic values of respiratory disturbances (among others, average and longest duration of various apnea and hypopnea, average and minimum oxygen saturation) were investigated during nicotine and control nights. All characteristic values, with the exception of the average oxygen saturation (from 93.7 to 94.4%, p < 0.02), did not change significant. These results indicate that nicotine could be an effective drug. However, it cannot yet be recommended for the treatment of obstructive sleep apnea because of some still unanswered questions (efficacy for non-smokers, side-effects, risk of addiction).

Administration, Cutaneous↗
PubMed1994

[Initiation of therapy in the sleep apnea syndrome using continuous positive pressure respiration].

BACKGROUND: Continuous positive airway pressure is the most important therapeutic method of sleep apnea syndrome (SAS). The prerequisite for its initiation is assessment of the optimal positive pressure and adaptation of the patient to this treatment. The basic criterium for assessment of positive pressure is elimination of apnoic intervals. The objective of the present work was to evaluate the optimal positive pressure CPAP according to the continuity of sleep and the appearance of an abnormally long (longer than 30 mins.) episode of REM sleep ("REM rebound"). METHODS AND RESULTS: CPAP was indicated in 13 patients with SAS (12 men, 1 woman), mean age 52.1 +/- 8.8 (SD) years, mean body mass index (BMI) 37.4 +/- 10.5. Severe cases of SAS were involved and/or SAS associated with other diseases (acromegaly-2, hypertension-8, IHD-4, chronic bronchopulmonary obstruction-3, and stroke-1). During one-night polysomnographic monitoring gradually the CPAP pressure was increased. Optimal positive pressure was signalized in addition to indicators of ventilation by uninterrupted sleep and "REM rebound". For treatment equipment of SEFAM Co. was used: 2x Pression+, 7x REM+, 4x REM+Control. Two patients refused CPAP treatment during the adaptation night. Eleven patients accepted CPAP treatment. The mean positive pressure value was 10.4 +/- 3.0 mbar. Assessment based on "REM rebound" was possible in six patients and based on continuity in 5 patients. Later pressure changes were called for in one patient (during adaptation he did not have "REM rebound"). CONCLUSIONS: Assessment of the optimal CPAP pressure as the lowest positive pressure compatible with regular breathing, as well as stabilized normal oxygen saturation of peripheral blood, continuous sleep and possibly "rebound" REM sleep proved useful.

Adult↗
PubMed1997

[Optical stimulation method (Snore-Stop) and tongue retainer (Snore-Master) without relevance in therapy of obstructive sleep apnea and snoring].

Recently intra- und extraoral devices are increasingly used in order to treat obstructive sleep apnea and snoring. We examined the value of an optically stimulating system ("eye-cover", Snore-Stop) and a tongue-retainer (Snore-Master) as treatment of the obstructive sleep apnoe or snoring. In case of the eye-cover is a microphone integrated, which detects acoustic signals (e.g. snoring). After detection of snoring optical stimuli are generated in front of the eyes. This is intended to induce an arousal of the patient, without awaking him, causing a change of body position and this reduces the snoring or apneas. For the examination of the eye-cover in 26 patients (23 men, 55.6 +/- 10.3 years) polygraphic studies were performed while sleeping one night with the eye-cover and one night without, respectively. Visual analogue scales (VAS) were used in order to measure quality of life and sleep and the adverse effects of the device. To examine the tongue-retainer 14 patients (13 men, aged 52.9 +/- 11.8 years) were measured polygraphically. Again the subjective scores were assessed using the VAS. The principle of the tongue-retainer is to create a hollow space in front of the teeth, in which the tongue is positioned. Fixation of the tongue in this ventral position is thought to enlarge the mesopharyngeal area in order to reduce the upper airway obstruction. For both devices the index of snoring, the apnea-hypopnea-index, the index of desaturation, the mean and minimal SaO2 and SaO2 < 90 % in % of the night did not change significantly. Furthermore the subjective perception of the patients concerning their quality of sleep and life did not change. Moreover, despite of an adequate adaptation-period the use of the tongue-retainer was associated with considerable adverse effects. Neither the eye-cover nor the tongue-retainer could improve the severity of obstructive sleep apnoe or snoring.

Adult↗
PubMed1988

[Sleep-apnea syndrome. Elucidation, therapy and course].

Of 22 patients investigated for sleep disorders, habitual snoring and/or daytime hypersomnolence, 12(10 men) had obstructive sleep apnea syndrome (OSAS). 3 OSAS were mild, 5 moderate and 4 severe. The leading symptoms were daytime hypersomnolence and habitual snoring. As risk factors we found retro-micrognathia in 2 patients, macroglossia secondary to acromegaly in 1, alcohol abuse in 7 and obesity in 6. Conservative measures improved the disorder subjectively in 6 patients. One patient had a relapse 6 months after uvulopalatopharyngoplasty. 4 patients were successfully treated by nasal CPAP. Other diagnoses were idiopathic alveolar hypoventilation (2), Cheyne-Stokes breathing secondary to low cardiac output (1), monosymptomatic narcolepsy (2), sleep disturbances secondary to depression (2), chronic benzodiazepine abuse (1) and chronic bronchitis without nocturnal hypoxemia (1). History, clinical observation and oxymetry make diagnosis possible in most cases of OSAS severe enough to require treatment. Polysomnography is time-consuming and should be reserved for selected cases.

Adult↗
PubMed1997

[Do patients with obstructive sleep apnea syndrome treated with nCPAP therapy lose weight?].

A simple therapy for obstructive sleep apnoea syndrome is weight reduction, which we always recommend before initiating and maintaining nCPAP-therapy. We documented the body weight of 123 patients (9 women, 114 men; age 53.8 +/- 10 years, initial apnoea-hypopnoea-index 40.7 +/- 22.6/hour) before and after 582 +/- 391 days nCPAP-therapy. Absolute and relative (Broca Index: weight [kg]/[height [cm] -100] x 100) body weight was 97.8 +/- 19.4 kg resp. 128.3 +/- 24.3 units before and 97.3 +/- 18.2 kg resp. 127.8 +/- 23.5 units during therapy (not significant). Body weight changes ranged from +22 to -26 kg. Only a subgroup of patients with a Broca index between 100-119 exhibited a significant weight change from 86.8 +/- 10.4 to 88.5 +/- 10.4 kg. We conclude that our recommendations to lose weight were unsuccessful in patients with obstructive sleep apnoea, although nCPAP-therapy generally improved well-being.

Adult↗
PubMed2006

[Improvement of cardiopulmonary exercise capacity in patients with obstructive sleep apnea syndrome under CPAP therapy].

BACKGROUND AND PURPOSE: Obstructive sleep apnea syndrome (OSAS) is regarded as a cardiovascular risk factor. Therefore, cardiopulmonary exercise capacity in patients with OSAS before and under treatment with continuous positive airway pressure (CPAP) was investigated. PATIENTS AND METHODS: Cardiopulmonary exercise capacity was investigated in 36 patients with untreated OSAS using spiroergometry. A follow-up after at least 6 months was performed in 17 of these patients being treated with CPAP and in eight CPAP-neglecting patients, who served as controls. RESULTS: Maximum oxygen uptake ( O(2max)) was significantly reduced in all 36 patients with untreated OSAS (17.68 +/- 6.1 ml/min/kg) compared with reference values (30.72 +/- 4.9 ml/min/kg; p < 0.001). After an average of 305.7 +/- 104.8 nights of CPAP therapy, O(2max) rose from 15.33 +/- 4.8 to 18.53 +/- 6.9 ml/min/kg, whereas O(2max) remained unchanged in controls. Further spirometric parameters of exercise capacity as well as arterial blood pressure were also significantly improved under CPAP therapy. CONCLUSION: Cardiopulmonary exercise capacity is markedly reduced in patients with OSAS. Long-term CPAP therapy leads to a significant improvement of reduced cardiopulmonary exercise capacity in these patients.

Adult↗
PubMed1987

Transcutaneous monitoring as trigger for therapy of hypoxemia during sleep.

Based on results on central chemosensitivity in cats, paired stimuli were applied for therapy to infants with central respiratory insufficiency of various degrees. An unspecific respiratory stimulus, e.g. light for 1 s, was followed by a jet of either O2 or 2% CO2 in O2 for 1.5 s. The unspecific and the chemical stimuli were interspaced by 0.5 s. The combined stimulation was repeated every 10 s. The program was triggered by using threshold values of transcutaneous pO2. In infants with intratrachial tubes or tracheostoma we used the end tidal pCO2 for triggering the stimulation. The method could prevent hypoxemia during sleep in non-ventilated subjects with sleep apnea syndromes or in infants with severe hypoxemia during sleep after being rescued from Sudden Infant Death Syndrome (SIDS). In patients with Ondine's Curse Syndrome (OCS) with its CO2 insensitivity, paired stimuli were used in order to condition the chemical function of the respiratory system. Polysomnograms from 310 clinically healthy infants including healthy siblings of SIDS victims revealed instability of arterial pO2 and low CO2 sensitivity during sleep within the second month and the fourth to ninth month of life, respectively. These data challenge the described method as a potential preventive or therapeutic measure to defeat SIDS and sleep apnea syndromes in conjunction with disturbed chemical regulation of respiration.

Arousal↗
PubMed2006

Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels.

Recent studies suggest an association of obstructive sleep apnoea (OSA) with cardiovascular risk factors, such as dyslipidaemia. The present study analyses the effects of OSA and its therapy on serum lipid concentrations in 470 OSA patients in a single centre study. Multivariate regression showed a significant association between the apnoea-hypopnoea index and high-density lipoprotein cholesterol (HDL-C) serum levels (n = 366), independent of age, sex, body mass index, diabetes and lipid lowering medication. There were no independent associations with total cholesterol, triglyceride and low-density lipoprotein cholesterol serum levels. During follow-up (6 months) with effective bilevel or continuous positive airway pressure therapy in 127 patients (lipoproteins: n = 86) without change in their lipid lowering therapy, the mean HDL-C serum level increased significantly by 5.8% from 46.9+/-15.8 to 49.6+/-15.3 mg x dL(-1) (mean+/-SD). An independent relationship was found between the change of apnoea-hypopnoea index and the change of high-density lipoprotein cholesterol or triglycerides, respectively. All patients with abnormal serum lipid/lipoprotein levels improved significantly under bilevel or continuous positive airway pressure therapy. This study demonstrates an influence of obstructive sleep apnoea and its therapy on high-density lipoprotein cholesterol levels.

Analysis of Variance↗
PubMed1995

[Long-term follow-up of CPAP therapy in patients with obstructive sleep apnea].

The aim of the study was to investigate compliance of CPAP therapy in obstructive sleep apnea. CPAP therapy was adjusted in one night in the hospital. 104 patients (age 54.5 +/- 9.3 years) were asked by a standardized questionnaire for acceptance and side effects. 80% of the patients use CPAP regularly for 5.6 +/- 1.8 hours during the night. 51% use CPAP during the whole night. Patients and relatives report an improvement in clinical symptoms. The rate of side effects was high, only 11% were without any side effects. Major problems were skin problems under the CPAP mask (53%), 44% of patients reported dryness of the mouth, and 40% had problems with the noise of the unit. The rate of side effects as well as the short adjustment period for CPAP therapy did not seem to influence compliance.

Adult↗